3 stories this morning, for surgeons and the people who support them.
- BioRestorative Therapies takes a 1-for-20 reverse split to hold its Nasdaq listing while the Phase 2 BRTX-100 disc trial runs to its 52-week endpoint — Announced Sept 2, 2026 at 17:27 ET: BioRestorative's board approved a 1-for-20 reverse stock split, certificate of change effective 4:30 p.m. ET Sept 7, 2026, split-adjusted trading on Nasdaq from Sept 8, 2026. Shares outstanding drop from 27,622,556 (as of Aug 28, 2026) to approximately 1,381,128; authorized shares reduced from 1.5B to 75M. Stated purpose is regaining compliance with the $1.00 minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2). Second source: SEC Form 8-K exhibit, https://www.sec.gov/Archives/edgar/data/0001505497/000121390026096810/ea030438901ex99-1.htm . Trial context from the company's own Feb 10, 2026 release (https://www.globenewswire.com/news-release/2026/02/10/3235257/0/en/BioRestorative-Completes-Patient-Enrollment-in-Landmark-Phase-2-Trial-of-BRTX-100-for-Chronic-Lumbar-Disc-Disease.html): Phase 2 enrollment completed at 99 patients, prospective randomized double-blind sham-controlled, 2:1, single-level disease, intradiscal delivery of BRTX-100 (autologous hypoxically cultured mesenchymal stem cells); primary efficacy endpoints >30% ODI improvement and >30% VAS reduction at week 52; company stated it had begun Phase 3 enabling activities. Source
- GMReis completes the first US case with Quick Radius, a single-use distal radius kit built for ambulatory surgery centers — Reported Sept 2, 2026: GMReis completed the first US clinical case with the Quick Radius Distal Radius System, launching a single-use procedural platform aimed at ASCs. The set combines sterile implants with dedicated single-use instrumentation in one procedure-specific package, cutting dependence on reusable trays and the sterilization, inventory and OR-prep logistics around them; the company says it is the first of several single-use orthopedic procedural systems it plans for the US. Second source: Orthopedic Design & Technology, https://www.odtmag.com/breaking-news/gmreis-completes-first-u-s-quick-radius-case/ . Device detail from GMReis's earlier FDA 510(k) clearance for the Quick-Radius Disposable Set (https://www.orthoworld.com/gmreis-gains-fda-510k-clearance-for-quick-radius-disposable-set/): the set carries the VersaLock Volar Protect FLP plate, an anatomic volar locking plate with a central recess intended to reduce flexor pollicis longus tendon contact at distal plate positions, compatible with VersaLock 2.4 and 2.7 mm cortical and variable-angle (+/-15 degrees) locking screws. Source
- Nanochon treats the first patient in the Chondrograft first-in-human knee cartilage study, in Panama — Announced Sept 3, 2026; case performed Sept 2, 2026 at The Panama Clinic in Panama City by principal investigator Dr. Juan Osorio with Dr. Emilio Tufino. Chondrograft is a 3D-printed implant for focal articular cartilage defects of the knee, described by the company as bone-sparing and minimally invasive, providing immediate mechanical support for patients not yet candidates for joint replacement. The prospective first-in-human study enrolls patients 22-60 with femoral condyle or trochlear lesions who have failed conservative treatment; the company says a Level 1 multicenter randomized pivotal trial follows. The device holds FDA Breakthrough Device Designation; Panama's Ministry of Health approved the study (https://www.prnewswire.com/news-releases/nanochon-receives-regulatory-approval-from-panamas-ministry-of-health-to-initiate-first-in-human-clinical-study-of-chondrograft-302851955.html), registered at ClinicalTrials.gov as NCT07542184. Second source: ORTHOWORLD, https://www.orthoworld.com/nanochon-launches-first-in-human-clinical-study/ . Competitive context stated in the script: Smith+Nephew's CARTIHEAL AGILI-C aragonite-based osteochondral scaffold has been FDA approved since 2022 (https://www.smith-nephew.com/en/news/2026/04/21/new-data-for-cartiheal-agili-c-cartilage-repair-implant) and received a Category I CPT code announced Oct 9, 2025 (https://www.smith-nephew.com/en/news/2025/10/09/20251009-announces-new-category-i-cpt-code-for-its-cartiheal-agili-c-cartilage-repair-implant); Vericel's MACI has FDA approval for arthroscopic delivery (https://investors.vcel.com/news-releases/news-release-details/vericel-announces-fda-approval-and-commercial-availability-maci). Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.